Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Family Medicine | Nursing | Oncology | Urology | Journal

Back to Journal Articles

Selenium and/or Vitamin E Do Not Prevent Bladder Cancer

Last Updated: May 25, 2012.

 

No change in incidence for men treated with selenium or vitamin E alone or in combination

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
Neither selenium nor vitamin E alone or used in combination appears to prevent bladder cancer in men, according to a study published in the June issue of The Journal of Urology.

FRIDAY, May 25 (HealthDay News) -- Neither selenium nor vitamin E alone or used in combination appears to prevent bladder cancer in men, according to a study published in the June issue of The Journal of Urology.

In an effort to determine whether selenium or vitamin E had any preventive effect on the incidence of bladder cancer, Yair Lotan, M.D., of the University of Texas Southwestern Medical Center in Dallas, and colleagues conducted a secondary analysis using data from the Selenium and Vitamin E Cancer Prevention Trial, which included 34,887 men administered either selenium, vitamin E, both, or placebo in a double-blind fashion.

During a median follow-up of 7.1 years, 224 cases of bladder cancer were observed, primarily urothelial and nonmuscle invasive bladder cancer. Compared with those without bladder cancer, men with bladder cancer were older, more likely to be white, and more likely to have a history of smoking. There was no significant difference in bladder cancer incidence for men in the vitamin E (hazard ratio [HR], 1.05; P = 0.79), selenium (HR, 1.13; P = 0.52), or vitamin E plus selenium groups (HR, 1.05; P = 0.86), compared with placebo.

"This secondary analysis showed no preventive effect of selenium or vitamin E alone or combined on bladder cancer in this population of men," the authors write. "Further studies are needed to assess the effect in women, and at different doses and formulations."

One author disclosed financial ties to Alere and Adolor.

Abstract
Full Text (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.


Previous: Peritonitis Ups Odds of Mortality in Peritoneal Dialysis Patients Next: Pancreatectomy OK Without Downstaging From Therapy

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.